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Abstract
Introduction: The aim of this study was to collect data in France in patients with heparin-induced thrombocytopenia
who required parenteral anticoagulation and for whom other non-heparin anticoagulant therapies were
contraindicated including patients with renal failure, cross-reactivity to danaparoid or at high hemorrhagic risk.
Methods: A total of 20 patients, of mean age 72 ± 10 years, were enrolled in this open-label, multicenter clinical study.
Exploratory statistical data analysis was performed with descriptive interpretation of intra-individual comparisons using
simple univariate statistics.
Results: The diagnosis of HIT was confirmed in 16 subjects by an independent scientific committee. Fourteen patients
(70 %) were in an intensive care unit during the course of the study. Patients were treated with argatroban for a mean
duration of 8.5 ± 6.1 days. The mean starting dose of argatroban was 0.77 ± 0.45 μg/kg/min. Platelet recovery was rapid.
aPTT and anti-IIa activity assays were used to monitor the dose of argatroban. The mean baseline aPTT value was
45.0 ± 9.8 sec and increased to 78.2 ± 35.8 sec two hours after initiating argatroban. At this time mean argatroban
concentration was 0.34 ± 0.16 and 0.61 ± 0.28 μg/ml using ECT and TT measurements, respectively. New and/or
extended thromboses were reported in 25 % of patients and major bleedings were documented in 15 %. Six patients
died due to their underlying medical condition.
Conclusion: Considering its hepatic elimination and its short half-life, argatroban can be considered as a safe
therapeutic option in HIT patients at high hemorrhagic risk and with renal failure, particularly in an ICU setting.
Introduction
Heparin is one of the most widely used anticoagulants
for a variety of clinical conditions. One serious compli-
cation of heparin therapy is immune-mediated heparin-
induced thrombocytopenia (HIT), which can be associ-
ated with subsequent venous and arterial thrombosis.
For HIT patients an alternative parenteral anticoagulant
is always needed for the prevention of the thrombotic
risk associated with HIT and for the treatment of throm-
bosis related to HIT, or for continued anticoagulation. In
France the current authorized treatment options for
patients with HIT are danaparoid and argatroban. Dana-
paroid is a heparinoid factor Xa inhibitor [1]. It is renally
eliminated and has a long elimination half-life, increas-
ing the bleeding risk [2]. In addition, cross-reactivity be-
tween danaparoid and heparin antibodies can occur and
subsequently lead to new complications and unsatisfac-
tory outcomes [3].
Argatroban is a synthetic thrombin inhibitor that
offers potential benefit to patients with HIT. Argatroban
is unique among direct thrombin inhibitors (and other
anticoagulants) because it is predominantly hepatically
metabolized, acts rapidly and has a short elimination
half-life of 52 ± 16 minutes, ensuring rapid restoration of
hemostasis upon cessation of treatment [4], which is of
particular interest in elderly patients like those in our
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study. Argatroban does not cross-react with heparin-
dependent antibodies and does not induce antibody for-
mation [5].
Recently, the American College of Chest Physicians
Clinical Practice Guidelines [6] and Nordic Expert Panel
Clinical and Laboratory Guidelines [7] recommended
the use of argatroban in treating HIT patients with throm-
bosis and renal failure rather than other non-heparin
anticoagulants.
Argatroban was approved in Europe in 2004 [8]. The
aim of this study was to collect data in France in
patients with HIT who required parenteral anticoagula-
tion and for whom other non-heparin anticoagulant
therapies were contraindicated, including patients with
renal failure, cross-reactivity to danaparoid or at high
hemorrhagic risk. The goal was also to share experience
in biological monitoring of elderly intensive care unit
(ICU) patients using anti-IIa activity measured by modi-
fied thrombin time (TT) and ecarin clotting time (ECT).
Methods
Study design and patients
We conducted an open-label, multicenter clinical study
between September 10, 2009 and February 2, 2011 in 11
French centers where a total of 57 patients (older than
18 years) were screened if they had suspected HIT and
required parenteral anticoagulation. Only patients with a
local diagnosis of HIT with or without ongoing thrombosis
were finally included. Patients with uncontrolled bleeding
or severe hepatic impairment (Child-Pugh Class C) were
excluded.
The study was conducted in compliance with the
International Conference on Harmonization Good Clin-
ical Practice Guidelines and the Declaration of Helsinki.
The protocol was approved by the Independent Ethics
Committee and the French competent authority, ANSM
(Agence Nationale de Sécurité du Médicament). Each
patient provided written informed consent.
Diagnosis of HIT
Laboratory diagnosis of HIT was based on the positivity
of at least one of the following biological tests: an
enzyme-linked immunosorbent assay (ELISA), a platelet
aggregation test (PAT) or a serotonin release assay (SRA).
Clinical diagnosis was established by an independent sci-
entific committee (ISC).
Argatroban dosing
The recommended starting dose for this study was
1 μg/kg/min. Nevertheless, for patients with moderate
hepatic impairment (Child-Pugh Class B) or at risk of
decreased hepatic perfusion, such as those requiring
intensive care with congestive heart failure, multi-
system organ failure or following cardiac surgery, and
with hemorrhagic risk, the recommended starting
dose was 0.5 μg/kg/min.
Treatment was continued until anticoagulation was no
longer required or until adequate oral anticoagulation
was achieved. The aPTT value was checked at baseline
and 2 hours after starting treatment and the dose ad-
justed until the steady state aPTT was within the desired
therapeutic range (i.e., 1.5–3.0 times the pre-argatroban
baseline value as measured 10–60 minutes prior to the
start of infusion but not exceeding 100 seconds). Pa-
tients were assessed from baseline, during treatment and
24 hours after the end of argatroban infusion, with a
follow-up observation at 30 days after the end of the
treatment, or hospital discharge.
Monitoring of laboratory parameters
Laboratory tests were carried out in each participating
center using local protocols and methods to support
diagnosis and treatment. A centralized laboratory per-
formed clotting time measurements on the frozen
plasma samples from all sites on a BCS Coagulation
Analyzer (Siemens, Saint-Denis, France) to allow for com-
parison between patients and methods. Measurement of
the aPTT was performed using a PTT automate (Diagnos-
tica Stago, Asnières, France). Anti-IIa activity was deter-
mined using ecarin clotting time (ECT) and modified
thrombin time (TT). The modified TT was measured
using the Hemoclot® thrombin inhibitor assay (Hyphen,
Biomed, Neuville, France). The ECT was measured using
ecarin, a purified protease, (Diagnostica Stago, Asnières,
France) diluted in Hepes 0.025 M CaCl2 buffer at a final
concentration of 5 IU/ml. All clotting times were
expressed in seconds. ECT and TT measurements were
then converted into direct concentration units of arga-
troban (μg/ml) using the same calibration curve
(Hyphen, Biomed, Neuville, France).
Argatroban treatment outcome assessments
The primary endpoint was a composite of all-cause
death, thrombosis (new and extended) and amputation.
Secondary efficacy endpoints included the individual
components of the primary endpoint and death related
to HIT and major/minor bleeding. The laboratory effi-
cacy endpoints included time to platelet recovery, aPTT
and anti-IIa (onset and maintenance). All adverse events
(AEs) were documented, whether considered related or
not related in any way to the study drug(s). An inde-
pendent scientific committee (ISC) including clinicians
and biologists reviewed subject enrollment and adjudi-
cated HIT diagnosis and endpoints.
Statistical analysis
Exploratory statistical data analysis was performed with
descriptive interpretation of intra-individual comparisons
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using simple univariate statistics (mean, standard devi-
ation, median, minimum, maximum, differences to base-
line; paired t test percentages and confidence intervals if
applicable). All tests were two-sided at the 5 % level of sig-
nificance. In the case of significant departures from the
normal distribution as measured by a significant re-
sult of the Shapiro-Wilk test the data were evaluated with
Wilcoxon's signed-rank test (matched pairs).
Results
Heparin products had been given for prophylaxis in
12 patients (60 %) and/or therapeutic treatment in 10
patients (50 %).
HIT diagnosis
Of all 57 screened patients, 20 were included in the
study on the basis of a local diagnosis of HIT. Treatment
with argatroban was started as soon as the diagnosis of
HIT was confirmed. Therefore, an alternative (non arga-
troban) anticoagulant was given to 15 patients in the in-
terim period prior to diagnostic confirmation, for a
median duration of 3 days. Thirteen of these received
danaparoid, one received danaparoid, coumadin and clo-
pidogrel, and one subject received lepirudin.
In all 20 patients included, the mean platelet count at
heparin initiation was 204 ± 61 G/l and decreased to reach
a mean nadir platelet count of 56 ± 24 G/l (minimum 25,
maximum 113) after a period of 5 to 21 days. Each labora-
tory performed either an IgG-specific or a polyspecific
(IgG, IgA and/or IgM) ELISA. All 20 patients were tested.
Sixteen patients (80 %) had a positive result and four pa-
tients (20 %) were negative. Sixteen patients (80 %) were
tested for platelet aggregation. Ten patients (50 %) had a
positive result and four patients (20 %) were negative. In-
conclusive results were reported in two patients (10 %).
Only four patients (20 %) were tested for serotonin release
assay. A positive result was observed in three patients
(15 %) and an inconclusive result reported for one patient.
Overall, 14 patients had at least a positive ELISA and one
positive functional test. Patients 2 and 20 had only a posi-
tive ELISA with high optical density (OD) values, 2.97 and
3.31 respectively. Finally, the diagnosis of HIT was adjudi-
cated by the ISC in 16 patients (80 %). The four patients
for whom serological tests could not confirm the diagnosis
of HIT were still included in the study based upon the
strong clinical suspicion of HIT raised by the local physi-
cians. A summary is provided in Table 1.
Demographic and baseline characteristics
The population of the study included twenty patients
(14 male and 6 female) with a mean age of 72 ± 10 years
(range 41–85, median 73). The overall mean weight and
body mass index (BMI) were 78.4 kg (range 55.0–130.0,
median 74.5) and 28.1 ± 4.8 kg/m2 (range 21.5–40.2,
Table 1 Results of clinical and biological heparin-induced thrombocytopenia (HIT) diagnosis evaluation
Patient HIT experts opinion « 4T » score Polyspecific (IgG, IgA or IgM) ELISA OD/cutoff Platelet aggregation Serotonin release assay
1 Confirmed 5 1.72/0.52 Positive Positive n.a.
2 Confirmed 5 2.97/0.51 Positive Negative n.a.
3 Confirmed 7 2.73/0.51 Positive Positive n.a.
4 Confirmed 7 3.09/0.46 Positive Positive n.a.
5 Confirmed 4 >2.5/0.5 Positive Negative Positive
6 Confirmed 6 2.5/0.5 Positive n.a. Positive
7 Not confirmed 5 0.37/0.7 Negative n.a. n.a.
8 Not confirmed 5 0.18/0.12 Positive n.a. Inconclusive
9 Confirmed 8 1.56/0.4 Positive n.a. Positive
10 Confirmed 4 2.77/0.46 Positive Positive n.a.
11 Confirmed 7 0.84/0.38 Positive Inconclusive n.a.
12 Confirmed 6 1.89/0.47 Positive Positive n.a.
13 Confirmed 6 0.17/0.48 Negative Positive n.a.
14 Confirmed 5 0.93/0.43 Positive Positive n.a.
15 Confirmed 5 2.68/0.45 Positive Positive n.a.
16 Not confirmed 5 0.06/0.43 Negative Negative n.a.
17 Confirmed 5 2.41/0.46 Positive Positive n.a.
18 Not confirmed 6 0.08/0.43 Negative Negative n.a.
19 Confirmed 6 3.12/0.61 Positive Positive n.a.
20 Confirmed 6 3.31/0.45 Positive Inconclusive n.a.
Od optical density), n.a. not applicable, 4T Warkentin “4T” pre-test probability score [9]
Tardy-Poncet et al. Critical Care  (2015) 19:396 Page 3 of 11
median 27.5) respectively. The majority of patients were
in intensive care units (70 %) during the study and 65 %
of patients had moderate hepatic impairment (Child-
Pugh class B). Renal failure was observed in 14 patients
(70 %).
Bleeding and thrombotic risk factors were identified
for each patient. The majority of them combined mul-
tiple risk factors as expected in critically ill patients
(Table 2). Seventy percent of the study patients had
thrombosis at enrollment.
Argatroban therapy
The initial mean argatroban dose (± SD) was 0.77 ±
0.45 μg/kg/min (median 0.50, maximum 2.00 μg/kg/min),
the mean dose during treatment was 0.75 ± 0.4 μg/kg/min
and at the end of infusion the mean dose was 0.8 ±
0.60 μg/kg/min (median 0.54, maximum 2.15 μg/kg/min).
Thirteen patients had an initial dose ≤0.5 μg/kg/min and
seven patients had an initial dose ≥0.97 μg/kg/min. The
mean duration of argatroban treatment was 8.5 ± 6.1 days
(median 7.5 days).
Laboratory efficacy outcomes
The mean platelet count ± SD at baseline was 95 ± 55 G/l,
which increased to 147 ± 89 G/l at day 3 and to 215 ±
102 G/l 24 hours after the end of the infusion (EOI).
There was a statistically significant treatment effect on
platelet count at EOI + 24 hours (baseline vs. EOI +
24 hours, p <0.001; paired t test and Wilcoxon signed rank
test). The platelet count recovered (recovery defined as
50 % increase) in 12 of the 17 evaluable patients (60 %) at
day 3, and in 14 patients out of 16 evaluable patients
by EOI + 24 hours, with 10 of these patients reaching
a level ≥200 G/l.
The degree of argatroban anticoagulation was moni-
tored in the different local laboratories using aPTT and
anti-IIa activity (TT and ECT). As variability of measure-
ments between local laboratories may have a relevant
impact on the comparability of the results, all clotting
time measurements were centralized. The overall baseline
mean aPTT value increased from 44.8 ± 9.8 sec before the
start of infusion to a mean value of 78.1 ± 35.8 sec (ratio
1.7) within the first 2 hours after infusion and a mean
value of 73.8 ± 20.7 sec (ratio 1.6) during the entire period
under argatroban therapy. The mean value of 77.0 ±
31.1 sec at EOI, based on data from 12 patients who had
sufficient data at this time point, was similar to the value
at the 2-hour time point.
Figure 1 illustrates the overall course of the mean,
minimum and maximum aPTT values over time. It
shows a rapid increase in mean aPTT time at the 2-hour
time point after the start of the infusion and stabilization
from day 3 onwards, even if the majority of patients
were in intensive care units with frequent variability of
aPTT values. Measurement of the anticoagulation status
of the patient showed that anti-IIa values increased to
0.27 ± 0.31 using ECT at the 2-hour time point after the
start of the infusion, indicating the quick onset of action
of the argatroban treatment, and reached a final mean
value of about 0.34 ± 0.16 μg/ml at the end of the infu-
sion. As with ECT, argatroban concentration using
modified TT increased during the first 2 hours to 0.39 ±
0.29 μg/ml. The concentrations reached a final mean of
0.61 ± 0.28 μg/ml at the end of the infusion.
Following argatroban therapy five patients (25 %) bene-
fited from vitamin K antagonist bridge therapy which was
monitored using both international normalized ratio
(INR) and aPTT values.
Outcomes
Clinical efficacy and safety outcomes
In the study population during treatment and up to
30 days post argatroban treatment, deaths or amputa-
tion, or new and/or extended thrombosis were reported
in 10 patients (50 %) (Table 2). Six patients died during
the study. All deaths were assessed as being due to the
patients’ underlying disease (one patient with cardio-
genic shock, one with congestive heart failure, one with
refractory hypoxemia due to acute respiratory distress
syndrome (ARDS), one with multiple organ failure (MOF)
and refractory shock, one with sepsis with MOF and one
with degradation of their general condition, complicated
by renal azotemia). There were no amputations reported
in the 20 patients; in particular none of the 3 patients with
ischemic limbs had to undergo an amputation.
Five patients (numbers 4, 8, 9, 15 and 17) (25 %) expe-
rienced an episode of new and/or extended thrombosis
that was diagnosed up to 30 days after argatroban treat-
ment (Table 2). Four of them presented with HIT and
thrombosis before starting argatroban therapy. Two of
them had a prolonged baseline aPTT due to the pres-
ence of lupus anticoagulant (patient 4) and coagulation
disorders (patient 17), respectively. At the time of
thrombosis diagnosis patients 4, 8, 9 and 15 presented
with an aPTT value 1.4-fold to 2.0-fold greater than the
baseline value whereas the aPTT prolongation was more
than 2.0-fold greater than the baseline value for patient
17 (Table 3). Regarding the anticoagulant status of these
patients, results showed that the mean anti-IIa activity
value measured by modified TT ranged between 0.43
and 1.95 μg/ml as compared with 0.61 ± 0.28 μg/ml cor-
responding to the mean anti-IIa activity reported in the
study population throughout the duration of the treat-
ment (Table 4).
Four patients (numbers 3, 8, 14 and 17) (20 %)
reported a total of five bleeding events; three events
were adjudicated as major bleeding while the other two
events were adjudicated as minor (Table 3). At diagnosis
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Table 2 Summary of clinical efficacy outcomes by the Steering Committee




Major bleeding Bleeding Death
1 Gastric ulcer; renal failure Recent orthopedic surgery;
obesity; vena cava filter
Confirmed Yes x 2 No No No No
2 Antiplatelet treatment - Confirmed No No No No No
3 Cardiac surgery; renal failure AF Confirmed Yes No Yes, hematuria No Yes, cardiogenic shock
4 Antiplatelet treatment Obesity; DVT; PE; lupus
anticoagulant
Confirmed Yes x 2 Yes x 4 No No No
3 DVT extension
1 new
5 Antiplatelet treatment; renal
failure
Sepsis; AF Confirmed No No No No No
6 Acute renal failure; moderate
hepatic cystosis
DVT; sepsis Confirmed Yes No No No No
7 Renal failure; cardiac
insufficiency; liver insufficiency
DVT; PE Not confirmed Yes No No No Yes, congestive heart
failure
8b Acute renal failure; hepatic
insufficiency; gastric ulcer;
abdominal surgery; overdose





AF; cardiac insufficiency Confirmed Yes Yes, new-limb
ischemia
No No No
10 - Sepsis; DVT; PE Confirmed Yes x 2 No No No Yes, refractory hypoxemia
due to ARDS




Confirmed Yes x 2 No No No No
12 Hepatic impairment and
cardiac surgery
Cardiac surgery Confirmed No No No No No




Confirmed Yes No No No No





Confirmed Yes x 2 No Yes, rectorrhagia Yes,
hematemesis
Yes, MOF and refractory
shock









Not confirmed No No No No No
17 Acute renal failure; vascular
surgery
Obesity; AF; sepsis; arterial
thrombosis
Confirmed Yes Yes Yes, due to puncture
of dialysis catheter









Table 2 Summary of clinical efficacy outcomes by the Steering Committee (Continued)





Not confirmed Yes x 2 No No No Yes, degradation of general
condition complicated by
per-renal azotemia





Confirmed No No No No No




Confirmed No No No No No
Total 14 yes 5 yes 3 x major 2 x non
major
7 yes (1 died after end of
FU period); all deaths due
to underlying diseases
aBaseline thrombosis: all confirmed thromboses that were ongoing at the start of argatroban infusion. bPatient 8 had an overdose/medication error. The patient was infused 10.5 μg/kg/min for approximately 1 hour as
the study nurse mixed up two pumps. No major bleeding occurred. The death of this patient was not included in this study as it occurred outside the study period. cPatient 14 had Child Pugh class C at the time
of inclusion.
dPatient 19 was treated with danaparoid for 16 days before the start of the argatroban infusion. This patient was no longer in the acute HIT phase









of bleeding, these patients presented with an aPTT value
one-fold to four-fold greater than the baseline value.
The mean anti-IIa activity values measured by modified
TT ranged between 0.43 and 1.52 μg/ml as compared
with the mean anti-IIa activity reported in the study
population, 0.61 ± 0.28 μg/ml.
Adverse events
Amongst the reported AEs, 21 were considered to be
either possibly or probably related to argatroban treat-
ment (adverse drug reactions, ADRs) and they occurred in
nine patients who exhibited at least one thrombotic or
hemorrhagic factor (Table 2). The majority of these ADRs
were related to thrombotic and hemorrhagic events and
included pulmonary embolism, blue toe syndrome,
femoral artery embolism, jugular vein thrombosis, pelvic
vein thrombosis, rectal hemorrhage, puncture site
hemorrhage, and hematuria.
Discussion
HIT is considered a clinico-pathological syndrome for
which the diagnosis is based on thrombocytopenia with
or without thrombosis and the detection of heparin-
dependent antibodies [9]. Its recognition and diagnosis
remain challenging in the ICU setting [10–12]. In the
present study in which most of patients were in ICU, the
diagnosis of HIT was validated a posteriori in 16 out of
20 patients after adjudication by an ISC. The diagnosis
was based on a series of commonly used clinico-
biological criteria and supported by requirement for at
least one positive serological test. We note that sero-
logical confirmation of a diagnosis of HIT has been
rarely reported in previously published studies describ-
ing outcomes of argatroban-treated patients.
Because most of the study patients were at high
hemorrhagic risk the initial mean dose of argatroban
was low (0.77 ± 0.45 μg/kg/min). The recommended ini-
tial dosage of argatroban in adult patients without hep-
atic impairment is 2 μg/kg/min [13]. However, based on
clinical experience gained from past studies and from
marketed drugs, dosing schedules had to be optimized
according to specific subjects’ condition, particularly in
the case of ICU settings. To date there are limited pub-
lished data on dosing patterns for argatroban therapy in
the ICU. Maintenance doses of 0.125–0.91 μg/kg/min
have been reported in case reports and small studies of
4 to 65 patients [14, 15]. Furthermore, Saugel et al.
showed that argatroban should be initiated at a markedly
reduced dose of about one tenth to one eighth of the
recommended dose in ICU patients with multiple organ
dysfunction syndrome [16]. Moreover, initial infusions of
1.5–2 μg/kg/min in these patients have resulted in
supratherapeutic aPTTs and bleeding [14, 15]. One
group of authors suggested that passive hepatic conges-
tion, accumulation of metabolites, and/or interactions
with multiple medications used in the ICU may justify
lower dose requirements [17]. In the present study, where
most of the patients were treated in an ICU, low
Fig. 1 Activated partial thromboplastin time (aPTT) and anti-IIa activity measurements versus time. Each point is the mean of aPTT or ecarin
clotting time (ECT) or thrombin time (TT) values for a given time in all study patients
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Event during argatroban therapy aPTT at diagnosis of
the event (sec)
Dose of argatroban at
diagnosis of thrombosis
μg/kg/min
Anti-IIab (TT) at diagnosis
of thrombosis (μg/ml)
Mean anti IIab (TT)
(before diagnosis of
thrombosis) (μg/ml)
Patient 4 Obesity, lupus
anticoagulant
DVT + PE 51.9 D7: DVT extension; D16: DVT
extension (iliac vein) + blue toe
syndrome; D29: PE recurrence
Mean aPTT ± SD 1.7 0.64 0.43 ± 0.12
91.3 ± 6.3
Patient 8a Cancer; sepsis PE 37.1 D4: new DTV (femoral vein);
D16:thrombosis of the femoral
and left external iliac vein + right
jugular vein
49.5 10.5 (for 1 hour) 0.13 1.95 ± 2.82




36.8 D6: ischemia of the right lower
limb
61.6 1.75 1.06 0.87 ± 0.35
Patient 15 Sepsis Cerebral
ischemic lesions
39.9 D14: right internal jugular
thrombosis
54.9 1.19 0.47 0.61 ± 0.12
Patient 17 Obesity; AF;
sepsis
Peripheral ischemia 48.7 D3: obstruction of the right
femoral artery
135.8 0.8 1.44 1.51 ± 0.31
Hemorrhagic complications














Patient 3 Cardiac surgery; renal failure 54.7 Major bleeding at D21:
hematuria
63.9 0.62 0.61 0.43 ± 0.13
Patient 8 Acute renal failure; hepatic
insufficiency; gastric ulcer;
abdominal surgery; overdose
37.1 Minor bleeding after 2-hour
infusion: gums and nose
149.7 Medication error 6.15 n.a.
Patient 14 Renal failure; hepatic
insufficiency; cardiac surgery
63.9 Minor bleeding at D6:
hematemesis; major bleeding
at D9: rectorrhagia
66.6 0.12 0.66 0.67 ± 0.29
Patient 17 Acute renal failure; vascular
surgery
48.7 Major bleeding at D5:
puncture of a dialysis catheter
133 0.32 1.53 1.52 ± 0.22
aInfusion was stopped due to medication error. bAnti-IIa activity was expressed as argatroban concentration. Patients 4, 8, 9, 15 and 17 experienced an episode of new or extended thrombosis; patients 3, 8, 14 and 17










argatroban doses were sufficient to achieve the target
aPTT values, and were associated with a rapid reversal of
thrombocytopenia in the majority of patients. This initial
rate was in accordance with the one used in the study of
Link et al. (continuous infusion of 0.7 μg/kg/min), who in-
vestigated argatroban treatment in 30 critically ill patients
with HIT receiving continuous renal replacement therapy
[18]. In contrast, this dose was higher than the argatroban
dose applied in the study of Saugel et al. (0.24 μg/kg/min)
performed in 12 elderly patients with multiple organ dys-
function, probably reflecting the degree of illness severity
in these patients [16].
While under argatroban therapy we observed a rapid
reversal of thrombocytopenia in the majority of patients.
During argatroban treatment the aPTT assay is com-
monly used for therapeutic monitoring. In critically ill
patients, coagulation abnormalities are commonly found
and may prolong the baseline aPTT [19]. In the present
study the baseline aPTT was already prolonged in 13 pa-
tients. Importantly, abnormalities in the coagulation
tests associated with HIT may confound its management
when only a global coagulation assay is used to monitor
anticoagulation. Warkentin et al. raise the importance of
baseline elevation of aPTT prior to initiating anticoagu-
lant therapy in the risk of subsequent anticoagulation
failure due to aPTT confounding, which is misleading
with respect to indicating a patient’s true level of antic-
oagulation [20]. In this context alternative methods
allowing for measurement of actual concentration in pa-
tient plasma are of interest [21]. Anti-IIa activity has
been reported as a more specific monitoring parameter
for direct thrombin inhibitors (DTIs), in particular in
the ICU setting where close monitoring is needed [22].
The ECT and TT assays activate the clotting cascade at
the level of thrombin generation and neither of these
tests contains phospholipid. Consequently neither is
affected by variation of most of the coagulation fac-
tors or by the presence of lupus inhibitors [23, 24]. It
is noteworthy that the present study showed that the
two methods were not superimposable with higher
values with modified a TT compared with the ECT (ratio
TT/ECT of about 1.5).
Nevertheless, a common limitation in monitoring any
DTI with anti-IIa activity is the lack of well-defined
therapeutic concentration ranges. Indeed, the thera-
peutic ranges are generally based on prolongation of the
aPTT and not on drug concentration levels [21]. We ex-
trapolated a theoretical therapeutic range of argatroban
from an aPTT standard curve, which was established
using a control plasma pool spiked with different con-
centrations of argatroban, in the range of 0–3 μg/ml.
The aPTT of each argatroban concentration was mea-
sured and the results (aPTT (sec)/argatroban concentra-
tion (μg/ml) were plotted (data not shown); the range
for the aPTT of 1.5–3.0 times the baseline value corre-
sponds to a range of 0.25–1.5 μg/ml of argatroban. In
our study thrombotic complications occurred in five
patients (25 %). Interestingly, these five patients had
at least one thrombosis before argatroban initiation.
This observation suggests that patients with an initial
thromboembolic event at HIT diagnosis were more
likely to present a future thromboembolic event as
compared with only isolated thrombocytopenia, as already
suggested [25] and should probably receive higher doses
of argatroban. At the same time, dose limitation should be
driven by the presence of high hemorrhagic risk in these
patients. In our study the incidence rate of thrombotic
complications under argatroban therapy is in agreement
with that previously reported. Lewis et al. reported a pro-
spective, historical-controlled study evaluating the efficacy
and safety of argatroban as anticoagulant therapy; in
patients with isolated HIT a new thrombosis occurred in
8.1 % of argatroban-treated patients versus 22.4 % in
control patients with HIT, but in patients with HIT and
thrombosis (HITT) the incidence was 19.4 % in the
argatroban group versus 34.8 % in control patients with
HIT [26]. Our results are in agreement with this study,
with a higher incidence of new thrombosis in HIT patients
with initial thrombosis. Sakr et al. reported thrombotic
complications in 35.7 % of patients from a cohort of 88
surgical ICU patients with positive HIT antibodies treated
with danaparoid or argatroban [27]. Considering that the
initial mean dose of argatroban administered to our
patients was low due to both high hemorrhagic and
thrombotic risks, our study did not report more new
thromboses. Looking closely at patients who experienced
a new thrombosis, two patients, numbers 4 and 17, pre-
sented with a prolonged aPTT at baseline, due to the pres-
ence of lupus anticoagulant (patient 4) and probably
related to DIC (patient 17). Patient 4 experienced four epi-
sodes of thrombosis and was probably undertreated. In
patients with HIT and lupus anticoagulant who do not
respond to initial doses of infusion and may need the tar-
get aPTT increased, higher doses of argatroban should be
considered [28] and the monitoring should use anti-IIa
activity rather than aPTT. Patient 17 experienced one new
Table 4 Anti-IIa activitya
Time Concentration of argatroban
mean ± SD (μg/ml)
ECT 2 hours after start 0.27 ± 0.31
EOI 0.34 ± 0.16
TT 2 hours after start 0.39 ± 0.29
EOI 0.61 ± 0.28
aAnti-IIa activity was measured using ecarin clotting time (ECT) and thrombin
time (TT) and expressed as argatroban concentration. Data were determined
by the central laboratory. EOI end of infusion
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thrombotic episode. A baseline elevated aPTT related to
DIC can rise to much higher values under DTI therapy,
potentially suggesting, falsely, that the patient is over-
anticoagulated and making the monitoring particularly
difficult. It is therefore of interest to use anti-IIa activity as
well as aPTT. The anti-IIa values before diagnosis of
thrombosis and at diagnosis of thrombosis were high, sug-
gesting that the thrombotic event was not related to drug
under-dosing. Moreover, considering all study patients
who experienced a new episode of thrombosis and based
on the theoretical therapeutic range of argatroban concen-
trations mentioned above, only patient 4 was at the lower
limit of this window.
For other anticoagulants, Elalamy et al. reported 19 %
thrombotic complications (arterial or venous) in 114
HIT patients treated with danaparoid, in a multicenter,
retrospective, case-control study performed in seven
French University Hospital centers [25]. In a retrospect-
ive observational analysis in 181 patients with confirmed
HIT and treated with lepirudin, Tardy et al. reported that
13.8 % of patients experienced a thrombotic event [29].
A total of five bleeding events occurred in four patients,
of which three events were adjudicated as major bleeding
(15 %). In previous studies such events affected 5–20 % of
patients with HIT, depending on the treatment drug and
population studied [25, 27, 29]. Elalamy et al. found an
overall rate of major bleeding of 9 % in danaparoid-treated
patients and Tardy et al. reported 20.4 % of major bleeding
events in lepirudin-treated patients [25, 29]. Overall,
although indirect comparisons between studies should be
interpreted with caution, it appears that the incidence of
new thrombosis is higher with argatroban compared with
lepirudin and danaparoid. However, bleeding events tend
to be lower compared with lepirudin.
Study limitations
Regarding the limitations of this study, it has to be noted
that the sample was small. There were also certain con-
straints in that patients were generally not treated until
confirmation of diagnosis, which meant that other antico-
agulants such as danaparoid or lepirudin had to be used
after the onset of HIT, but before confirmative test results
were available and thus, before argatroban initiation. As a
result, in 15 patients there was a delay between confirmed
diagnosis of HIT and treatment, outside the 48-hour win-
dow. Adjudication by the ISC led to recommendations
later in the course of the study, to start treatment before
diagnosis was confirmed for patients in whom earlier
treatment might have been more beneficial.
Conclusion
As expected from its pharmacologic properties, argatro-
ban was well-tolerated in patients with renal impairment
who were mostly in the ICU. The overall risk–benefit
assessment of the ISC members was favorable for arga-
troban. In conclusion, it can be stated that considering
its hepatic elimination, its short half-life and the low rate
of hemorrhagic complications in the study patients,
argatroban can be considered as a safe therapeutic op-
tion in HIT patients at high hemorrhagic risk and with
renal failure, particularly in an ICU setting.
Key messages
 Argatroban can be considered as a safe therapeutic
option in elderly patients with HIT and at high
hemorrhagic risk, particularly in an ICU setting
 In critically ill patients, the dosing of argatroban
cannot be only adjusted with a global
anticoagulation assay, aPTT
 The use of aPTT in addition to anti-IIa measurement
is essential for argatroban monitoring
 The two methods, modified TT and ECT, used to
measure anti-IIa activity, are not superimposable
with higher values with TT compared with ECT
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